MF6.STU MagForce AG
- Market cap
- EUR 89.8K
- P/E
- -
- P/B
- 0.00x
- ROE
- -39.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2021.
Is MF6.STU undervalued?
Graham numberThe Graham number of MagForce AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MagForce AG fundamental analysis
No fundamental analysis for MagForce AG yet.
MagForce AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MagForce AG
MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
Full company profileMagForce AG financial statements
MagForce AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 67.2K | 840K | 621K | 352K |
| Gross Profit | -388K | 894K | 435K | -317K |
| Operating Income | 6.90M | -5.76M | 19.4M | -6.01M |
| EBITDA | 6.78M | -6.40M | 18.5M | -6.95M |
| Net Income | 4.36M | -8.73M | 14.7M | -10.6M |
| EPS | 0.16 | -0.32 | 0.50 | -0.35 |
| Balance Sheet | ||||
| Total Assets | 37.1M | 36.7M | 65.6M | 62.8M |
| Total Liabilities | 19.0M | 22.0M | 30.1M | 36.0M |
| Shareholders' Equity | 18.2M | 14.7M | 35.5M | 26.8M |
| Cash & Short-term Investments | 1.49M | 167K | 1.71M | 115K |
| Cash Flow | ||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 |
| Ratios | ||||
| ROE | 24.0% | -59.4% | 41.5% | -39.4% |
| ROA | 11.7% | -23.8% | 22.5% | -16.8% |
| Net Profit Margin | 6,485.2% | -1,039.4% | 2,374.1% | -3,004.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MagForce AG dividends
MagForce AG has not paid dividends in the last 4 fiscal years.
Who owns MagForce AG
- Insiders 0.00%
- Institutions 0.37%
- Public & others 99.63%
- Shares outstanding 29.9M
MagForce AG company profile
- Company name
- MagForce AG
- Ticker
- MF6.STU
- ISIN
- DE000A0HGQF5
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 33
- Fiscal year end
- December
- Address
- Max-Planck-Straße 3, Berlin, Germany, 12489
- Phone
- 49 30 308 380 0
- Website
- magforce.de
About MagForce AG
MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce AG management
4- Dr. Benjamin J. LippsChairman of the Management Board & CEO · born 1940
- Dr. Andreas JordanExecutive VP, Chief Scientific Officer & MD of Europe · born 1959
- Ms. Barbara Von FrankenbergVice President of Communications & Investor Relations
- Ms. Solveig SalomonVP of Marketing & Sales and European Commercial Director